MO, I don't see it being a best business sense
Post# of 72440
(Total Views: 269)
Posted On: 04/24/2018 1:15:35 PM
MO,
I don't see it being a best business sense to go it alone. If you have a major player as your partner they have the money for advertising, production, management, etc... Name recognition is also huge when it comes to marketing and getting doctors and insurance companies on board. Going it alone would require a large increase in fixed expenses, albeit mostly staff but there are plenty of other expenses that come with it to include insurance, the risk of something going wrong brings on potential lawsuits etc etc This is why I believe Leo and company stated they do not want to bring it to market, it takes experts to get every penny in value out. You also hold a bigger risk if another rival drug makes it to market in the years that you have the patent protection. The other issue I see is that IPIX wants to continue to develop other drugs already in the back log, with a deal you have money up front to start testing and advance other drugs. There are a couple other drugs that haven't been talk about in years that I would personally like to see hitting the table. They can't try to advance drugs that have less market value if they do not have a cash surplus. In the end it does all depend on what kind of game big pharma is playing and what the company feels it's value is.
The company has developed a lot of experience in successful trials and cash management, trying to take on other work loads seems like a much bigger risk than value it brings. Remember Leo and all are invested pretty heavily in the stock also. I think they go with the less risk, as the other option doesn't bring a much bigger payout.
GLTM
I don't see it being a best business sense to go it alone. If you have a major player as your partner they have the money for advertising, production, management, etc... Name recognition is also huge when it comes to marketing and getting doctors and insurance companies on board. Going it alone would require a large increase in fixed expenses, albeit mostly staff but there are plenty of other expenses that come with it to include insurance, the risk of something going wrong brings on potential lawsuits etc etc This is why I believe Leo and company stated they do not want to bring it to market, it takes experts to get every penny in value out. You also hold a bigger risk if another rival drug makes it to market in the years that you have the patent protection. The other issue I see is that IPIX wants to continue to develop other drugs already in the back log, with a deal you have money up front to start testing and advance other drugs. There are a couple other drugs that haven't been talk about in years that I would personally like to see hitting the table. They can't try to advance drugs that have less market value if they do not have a cash surplus. In the end it does all depend on what kind of game big pharma is playing and what the company feels it's value is.
The company has developed a lot of experience in successful trials and cash management, trying to take on other work loads seems like a much bigger risk than value it brings. Remember Leo and all are invested pretty heavily in the stock also. I think they go with the less risk, as the other option doesn't bring a much bigger payout.
GLTM
(9)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
Scroll down for more posts ▼